Establishment of nedaplatin safety dose formula based on renal function for combination chemotherapy with nedaplatin and 5-fluorouracil in patients with esophageal cancer-Reference-Cited by-同舟云学术

Establishment of nedaplatin safety dose formula based on renal function for combination chemotherapy with nedaplatin and 5-fluorouracil in patients with esophageal cancer

Published:2021-10-22 Issue:2 Volume:27 Page:348-353
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Takahashi Masaya,Takahashi Katsuyuki^ORCID,Muguruma Kazuya,Ohira Masaichi,Nagayama Katsuya

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-021-02057-w.pdf

Reference14 articles.

1. Kitagawa Y, Uno T, Oyama T et al (2019) Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus 16:1–24. https://doi.org/10.1007/s10388-018-0641-9

2. Kitagawa Y, Uno T, Oyama T et al (2019) Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus 16:25–43. https://doi.org/10.1007/s10388-018-0642-8

3. Kato K, Muro K, Ando N et al (2014) A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI). Esophagus 11:183–188. https://doi.org/10.1007/s10388-014-0427-7

4. Shimada M, Itamochi H, Kigawa J (2013) Nedaplatin: a cisplatin derivative in cancer chemotherapy. Cancer Manag Res 5:67–76. https://doi.org/10.2147/CMAR.S35785

5. Zhang F, Wang Y, Wang Z-Q et al (2016) Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis. Dis Esophagus 30:1–8. https://doi.org/10.1111/dote.12490